Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Table 2 Top 10 adverse effects (all grade) associated with pazopanib versus sunitinib

Adverse effects	The number of study	Pazopanib group (event/total)	Sunitinib group (event/total)	RR (95% CI)	P value	Heterogeneity
Adverse effects	The number of study	Pazopanib group (event/total)	Sunitinib group (event/total)	RR (95% CI)	P value	I² (%)	P value
Diarrhea	3	378/714	413/1210	1.11 [1.01–1.23]	0.03	11	0.32
Fatigue	3	350/714	542/1190	0.87 [0.79–0.96]	0.006	0	0.64
Hypertension	4	761/1241	783/1747	1.04 [0.99–1.10]	0.15	54	0.09
Nausea/Vomiting	3	434/719	531/1225	0.95 [0.88–1.02]	0.15	80	0.006
Leukopenia	2	258/626	477/648	0.55 [0.50–0.61]	< 0.00001	0	0.90
Thrombocytopenia	3	259/719	529/1225	0.54 [0.48–0.60]	< 0.00001	0	0.47
Neutropenia	3	227/719	447/1225	0.54 [0.48–0.61]	< 0.00001	0	0.57
Increased creatinine	2	190/626	284/648	0.68 [0.59–0.79]	< 0.00001	0	0.35
Increased AST	2	359/626	358/648	1.02 [0.93–1.12]	0.67	0	0.96
Increased ALT	2	351/626	266/648	1.35 [1.20–1.51]	< 0.00001	11	0.29

ISSN: 1471-2407